Noticias de PCVX_US
Noticias del mercado
Últimas noticias sobre PCVX_US — 252 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Vaxcyte Inc. stocks have been trading up by 51.38 percent amid highly positive sentiment surrounding its leading vaccine pipeline. Key Takeaways BofA trimmed its PCVX price target to $130 from $133 but kept a Buy rating, assigning a high 75% chance of success to the pivotal OPUS-1 Phase 3 trial of VAX-31. The OPUS-1 readout…
Vaxcyte Inc. stocks have been trading up by 52.09 percent, driven primarily by strong clinical progress and regulatory momentum. Key Takeaways BofA slightly trimmed its PCVX price target from $133 to $130 but reaffirmed a Buy rating and a 75% success probability for the pivotal OPUS-1 Phase 3
James Wassil incluyó a UBS Financial Services como corredor para la venta de acciones ordinarias propuesta, con una fecha de venta aproximada del 5 de octubre de 2026.
SAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and...
Vaxcyte will present Phase 3 trial data for its 31-valent pneumococcal vaccine, VAX-31, on October 5
Price-action only: Vaxcyte Inc. (PCVX) movements set the tone for institutional models. Discipline and Rules-Based Execution in PCVX Response
Página 9 de 13